KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $170.1 million.

  • Vir Biotechnology's Cash & Equivalents rose 103.0% to $170.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.1 million, marking a year-over-year increase of 103.0%. This contributed to the annual value of $222.9 million for FY2024, which is 771.14% down from last year.
  • As of Q3 2025, Vir Biotechnology's Cash & Equivalents stood at $170.1 million, which was up 103.0% from $211.1 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Cash & Equivalents registered a high of $1.5 billion during Q2 2022, and its lowest value of $160.7 million during Q1 2024.
  • In the last 5 years, Vir Biotechnology's Cash & Equivalents had a median value of $452.1 million in 2023 and averaged $533.9 million.
  • Per our database at Business Quant, Vir Biotechnology's Cash & Equivalents skyrocketed by 20958.45% in 2021 and then tumbled by 8051.78% in 2024.
  • Over the past 5 years, Vir Biotechnology's Cash & Equivalents (Quarter) stood at $347.8 million in 2021, then soared by 143.99% to $848.6 million in 2022, then tumbled by 71.53% to $241.6 million in 2023, then fell by 7.71% to $222.9 million in 2024, then fell by 23.71% to $170.1 million in 2025.
  • Its Cash & Equivalents was $170.1 million in Q3 2025, compared to $211.1 million in Q2 2025 and $273.6 million in Q1 2025.